Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 10 of about 178 citing Ahrén: Improved meal-related β-cell function and insulin sensitivity by the dipeptidyl.... (0.09 sec) 

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl …


DJ Drucker, MA Nauck - The Lancet, 2006 - Elsevier
Glucagon-like peptide 1 (GLP-1) is a gut-derived incretin hormone that stimulates insulin and
suppresses glucagon secretion, inhibits gastric emptying, and reduces appetite and food
intake. Therapeutic approaches for enhancing incretin action include ...
Cited by 416 - Related articles - All 10 versions

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic …


P Aschner, MS Kipnes, JK Lunceford, M Sanchez, … - Diabetes Care, 2006 - Am Diabetes Assoc
RESULTS—Sitagliptin 100 and 200 mg produced significant (P < 0.001) placebo-subtracted
reductions in A1C (−0.79 and −0.94%, respectively) and fasting plasma glucose (−1.0
mmol/l [−17.1 mg/dl] and −1.2 mmol/l [−21.3 mg/dl], respectively). Patients with baseline ...
Cited by 195 - Related articles - BL Direct - All 13 versions

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as …

- januvia.se [PDF] 
I Raz, M Hanefeld, L Xu, C Caria, D Williams-Herman, … - Diabetologia, 2006 - Springer
Abstract Aims/hypothesis The aim of this study was to assess the efficacy and safety of sitagliptin
(MK-0431) as mono- therapy in patients with type 2 diabetes mellitus and inadequate glycaemic
control (HbA 1c Q7% and e10%) on exercise and diet. Methods A total of 521 patients ...
Cited by 167 - Related articles - All 5 versions

Gateways to clinical trials


M Bayes, X Rabasseda, JR Prous - Methods and findings in …, 2006 - journals.prous.com
Contributing Editors: P. Cole, C. Orellana, JA Vallès, RM a . Antonijoan, KP Mohana Priya,
M. Priya, V. Renuga, R. Sree Lekha, B. Priya, A. Tomillero, G. Krithiga and E. Banu Rekha.
Cited by 148 - Related articles - All 9 versions

Efficacy and tolerability of initial combination therapy with vildagliptin and …


J Rosenstock, MA Baron, R Camisasca, F … - Diabetes, Obesity …, 2007 - interscience.wiley.com
It is also possible that your web browser is not configured or not able to display style sheets.
In this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the latest version of Microsoft or Mozilla web browser to ...
Cited by 111 - Related articles - All 5 versions

Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes


V Fonseca, A Schweizer, D Albrecht, MA Baron, I … - Diabetologia, 2007 - Springer
Abstract Aims/hypothesis Type 2 diabetes is difficult to manage in patients with a long history
of disease requiring insulin therapy. Moreover, addition of most currently available oral antidiabetic
agents increases the risk of hypoglycaemia. Vildagliptin is a dipeptidyl peptidase-IV ...
Cited by 105 - Related articles - BL Direct - All 4 versions

{beta}-Cell Failure in Diabetes and Preservation by Clinical Treatment

- endojournals.org
BL Wajchenberg - Endocrine reviews, 2007 - Endocrine Soc
There is a progressive deterioration in ß-cell function and mass in type 2 diabetics. It was found
that islet function was about 50% of normal at the time of diagnosis, and a reduction in ß-cell
mass of about 60% was shown at necropsy. The reduction of ß-cell mass is attributable to ...
Cited by 105 - Related articles - BL Direct - All 7 versions

Comparison between vildagliptin and metformin to sustain reductions in HbA1c …


A Schweizer, A Couturier, JE Foley, S … - Diabetic Medicine, 2007 - interscience.wiley.com
It is also possible that your web browser is not configured or not able to display style sheets.
In this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the latest version of Microsoft or Mozilla web browser to ...
Cited by 90 - Related articles - BL Direct - All 4 versions

Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1


MC Riddle, DJ Drucker - Diabetes Care, 2006 - Am Diabetes Assoc
Current therapies for type 2 diabetes are frequently associated with inadequate control of postprandial
hyperglycemia, weight gain, and, in the case of oral agents, loss of efficacy over time. A better
understanding of physiological responses to meals is leading to the development of new ...
Cited by 72 - Related articles - BL Direct - All 10 versions

[PDF] DPP-4 inhibitors and their potential role in the management of type 2 diabetes


A Barnett - International journal of clinical practice, 2006 - nerdoc.wordpress.com
The dipeptidyl peptidase 4 (DPP-4) inhibitors enhance the body's own ability to control blood
glucose by increas- ing the active levels of incretin hormones in the body. Their mechanism of
action is distinct from any existing class of oral glucose-lowering agents. They control ...
Cited by 69 - Related articles - View as HTML - BL Direct - All 7 versions


Result Page: 

1

2

3

4

5

6

7

8

9

10

Next


 


Go to Google Home - About Google - About Google Scholar

©2009 Google